Which phosphate transporters should be targeted to reduce hyperphosphatemia?


NaPi-IIb, a type II sodium-dependent phosphate transporter, is considered a dominant transporter in rodents for phosphate absorption in the small intestine. However, the regulation of its expression in chronic kidney disease (CKD) is still ambiguous. A recent study measured protein expression level of NaPi-Iib in CKD-rats by mass spectrometry to evaluate the extent of phosphate transport via this molecule. The results showed that  the contribution of NaPi-IIb to intestinal phosphate absorption dramatically decreases in CKD, suggesting that in order to improve handling of hyperphosphatemia in CKD it is mandatory to inhibit other phosphate transporters as well.

Read the full article here: https://academic.oup.com/ndt/advance-article/doi/10.1093/ndt/gfaa156/5900877